Skip to content
Search

Latest Stories

NPA will become more “militant” as wait for pharmacy contract goes on

NPA members are expected reduce opening hours and services from next week

NPA members are expected reduce opening hours and services from next week

Pic credit: iStock

The government has been warned by the National Pharmacy Association (NPA) that community pharmacy will not back down from collective action and reducing opening hours from April 1st.

NPA board member, Ashley Cohen, told LBC today that the sector was in a "desperate situation" and that the representative body will do “whatever we can to protect our sector”.


“We're becoming more angry, more frustrated and more militant as the weeks and the months go by and getting to a point to almost say that ‘enough is enough’,” said Cohen.

Pharmacy minister Stephen Kinnock previously told Pharmacy Business that he was “disappointed” by the NPA’s decision to push for collective action and that the government was “working at pace and have rolled up our sleeves to resolve the issues”.

However, pharmacies have seen around a 40 per cent cut to this funding in real terms since 2017, forcing record numbers to close. Around 1,300 pharmacies have shut down since 2017 including 29 since January.

Additional unfunded costs due to hit pharmacies on April 1st include National Insurance, National Living Wage and Business rates, on top of a decade of real terms cuts which may jeopardise patient safety if a resolution is not found.

The NPA announced last week that will advise its 6000 member pharmacies in England to take the unprecedented step in the face of what it has described as an April cliff-edge that will see a range of financial burdens placed on the sector.

“Is it best for us to reduce our opening hours rather than to close permanently? I would have thought that the latter would be the case,” said Cohen, who is also chair of Community Pharmacy West Yorkshire.

“However inconvenienced it might be, we need to do something and be in control of our decisions. So maybe reducing our hours, reducing some services to protect the sector in the long term is what's needed at the moment. But as soon as we do get a settlement, we can very quickly stop this collective action.

“It's taken many years and many unanswered questions in terms of the government, to get to this state.”

Cohen revealed that in the last 12 months, he has had to put in £125,000 of his own money just to keep his business going.

He explained how the rise in NI contributions will have a massive impact on community pharmacies.

“We are a profession and what's really vitally important is that we have a contract with the government, which represents up to 90 per cent of our funding. So unlike other businesses that may be able to increase their prices or make some changes, we can't do that, we're held to a government contract, a contract that has been static for nearly a decade now,” he said.

“In some respects, I feel that we are treated a little bit like second class citizens in healthcare, where family doctors, our GP colleagues, are basically felt as part of the NHS family - but we're referred to as businesses even though our contract is very similar, almost identical to GP contracts and that's frustrating.”

More For You

Pharmacist Support calls for birthday donations to meet rising demand for mental health services

More and more pharmacy professionals are reaching out for help, said Danielle Hunt.

Pharmacist Support's birthday appeal: Donate to address growing mental health demand

Pharmacist Support – the independent charity dedicated to the pharmacy profession – is celebrating 184 years of service with the launch of a special birthday donations appeal.

On 15 April, the charity is urging individuals and organisations across the sector to support its campaign to raise vital funds to meet the increasing demand for its mental health and wellbeing services.

Keep ReadingShow less
Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less
NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less